
An experimental drug for the neurological disorder ALS was approved in Canada on Monday, but an ongoing evaluation of the treatment by the U.S. Food and Drug Administration has raised questions about its effectiveness. A condition of Health Canada’s approval of Albrioza (AMX0035) calls for Massachusetts-based drug maker Amylyx Pharmaceuticals later to provide better evidence… read on > read on >